Licensing status

Publication and contact information


Graft rejection

IL-7; IL-7 receptor (CD127)

Mouse studies suggest inhibiting IL-7 signaling could help prevent graft rejection. In a mouse model of diabetes, injection of an IL-7 receptor-blocking antibody starting 3 weeks before transplantation of pancreatic islets and continuing for 90 days post-transplantation increased graft survival and decreased formation and activation of donor-specific memory T cells compared with no treatment or with injection of the antibody at the time of transplantation. In a skin transplantation mouse model, IL-7 receptor blockade following T cell depletion prolonged graft survival to 58 days from 30 days. Next steps include testing safety and immunological features of an anti-human IL-7 receptor mAb in nonhuman primates.

SciBX 7(18); doi:10.1038/scibx.2014.534
Published online May 8, 2014

Patent application filed covering anti-IL-7 receptor mAbs; licensing status undisclosed

Mai, H.-L. et al. J. Clin. Invest.; published online April 1, 2014;
Contact: Jean-Paul Soulillou, Institut National de la Santé et de la Recherche Médicale (INSERM) UMR 1064, Nantes, France